The HELZ Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population of HeLa cells with targeted disruption of the HELZ gene, serving as a loss-of-function model for studying HELZ-dependent processes. This heterogeneous pool retains the genetic diversity of an uncloned edited population, avoiding selection biases inherent to monoclonal cell lines. Disruption of HELZ eliminates its protein function, enabling researchers to dissect its role in post-transcriptional regulation.
The host HeLa cell line is an immortalized epithelial line from a cervical adenocarcinoma, originally established from Henrietta Lacks. As a widely utilized human cancer model, HeLa cells provide robust proliferation and genetic tractability, making them an ideal platform for CRISPR/Cas9-based knockout generation to investigate cellular mechanisms in a neoplastic context.
HELZ encodes a superfamily I RNA helicase that localizes to cytoplasmic processing bodies (P-bodies) and stress granules, where it facilitates mRNA decapping and translational repression. As part of the mRNA surveillance and degradation machinery, HELZ interacts with decapping components DCP1A and DCP2, the 5??C3?? exonuclease XRN1, and scaffold proteins LSM14A, DDX6, and EDC4. Its activity is stimulated by cellular stress and mTOR signaling, leading to translational silencing and accelerated decay of target mRNAs, thereby controlling post-transcriptional gene expression programs.
In the HeLa cervical adenocarcinoma background, HELZ knockout provides a unique tool to examine how RNA helicase-mediated mRNA turnover impacts cancer cell biology. Loss of HELZ disrupts P-body and stress granule organization, potentially altering the stability of transcripts encoding oncogenes, cell cycle regulators, and stress response factors. This model holds particular relevance for investigations into colorectal and cervical cancers, where dysregulation of RNA decapping and decay pathways contributes to malignant progression.
This polyclonal knockout pool is suitable for diverse assays, including western blotting to assess HELZ and core decapping factor levels, RT-qPCR to determine target mRNA half-lives, RNA immunoprecipitation for studying RNA?Cprotein interactions, immunofluorescence to visualize P-body markers such as DCP1A and DDX6, luciferase-based translational repression reporters, and stress granule induction with sodium arsenite or heat shock. These applications enable detailed analysis of HELZ’s role in mRNA metabolism and stress responses within a cancer cell environment. For further information, please contact Ascent Research.
